ABBV vs INCY
By Alex · Tickerpine
AbbVie Inc. vs Incyte Corporation, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | INCY |
|---|---|---|
| Price | $253.35 | $113.75 |
| Market cap | $447.62B | $22.73B |
| P/E ratio | 123.6 | 16.1 |
| ROE | — | 30.82% |
| Profit margin | 5.79% | 26.71% |
| Revenue growth | 12.40% | 20.90% |
| Dividend yield | 2.73% | — |
| Beta | 0.31 | 0.79 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs INCY in plain English
- ABBV is the bigger company — about 19.7× the market cap of INCY.
- INCY is cheaper on earnings (P/E 16.1 vs 123.6).
- INCY is growing revenue faster (21% vs 12%).
- ABBV pays a dividend (2.73%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
INCY return calculator
See what $1,000 in Incyte Corporation would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.